

## Special Issue

# Biofilm-Associated Vaginal Infections

### Message from the Guest Editors

Bacterial vaginosis (BV) is the most common vaginal infection worldwide in women of reproductive age. Despite extensive research over the past 50 years, the etiology of BV remains unclear. However, it is certain that BV involves the presence of a multi-species biofilm on vaginal epithelial cells, where *Gardnerella* species presumably play a pivotal role. Similar to what happens in many other biofilm infections, traditional antimicrobial therapies are unable to fully eradicate the vaginal biofilm, and unfortunately, this often leads to high recurrence rates of BV. In an attempt to overcome antimicrobial therapy failure and recurrence, new strategies including antiseptics, biofilm-disrupting agents, probiotics, endolysins, and plant-derived products, have been proposed as emergent and valuable approaches to treat BV. This Special Issue seeks manuscript submissions that further our understanding of the role of BV-associated biofilms in antimicrobial resistance. Submissions related to the response of vaginal pathogens to novel strategies that have been proposed to treat BV are especially encouraged.

---

### Guest Editors

Dr. Joana Castro

Dr. José António Baptista Machado Soares

Prof. Dr. Christina A. Muzny

---

### Deadline for manuscript submissions

closed (31 December 2021)



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/78860](https://mdpi.com/si/78860)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)